Stemtrix Corporation

Stemtrix Corporation has developed a new highly effective solution an antibacterial drug that is an alternative to antibiotics. Global crisis: The widespread and uncontrolled use of antibiotics has given rise to the spread of antibiotic-resistant strains. Innovations in the treatment of infectious diseases. Radical reduction in the use of antibiotics in veterinary medicine and medicine. Instead of killing the bacteria, the drugs put them into a vegetative state, blocking their ability to cause disease. The mission of Stemtrix Corp. is to bring to the market a group of drugs for the treatment of infectious diseases, which will allow: to avoid the development and block the existing mechanisms of resistance; reduce the virulence and size of pathogen populations. The widespread and uncontrolled use of antibiotics has given rise to the spread of antibiotic-resistant strains. One of the reasons is the industrial use of antibiotics in the rearing of farm animals, technologically providing for their use to ensure proper productivity. Stemtrix preparations do not kill, but serve as mediators of the transition of their pathogens from an active state to a vegetative one. Stemtrix is a radical reduction in the use of antibacterial drugs and antibiotics. The drugs are intended for the prevention and treatment of intestinal and other inflammatory infections of a bacterial nature. Our medications can be used in the tretment of the large number of diseases: gastrointestinal tract, urogenital pathways, skin, ear. Combination therapy is possible, including the use of the drug and any antibacterial agent. The obtained results of the study of the use of Rezovet in production conditions give grounds for its use as an effective tool for the prevention and treatment of such bacterial infections as: hemophilosis, colibacillosis, mycoplasmosis, pasteurellosis, pullorosis, necrotic enteritis, salmonellosis and its use in the standard scheme of poultry rearing. Rezomast does not contain antibiotics, does not have waiting periods for milk, has a stable and long-lasting therapeutic efficacy, helps to stop inflammatory changes in the breast tissue and reduces the risk of recurrence of the disease. The results of the study of the use of Rezomast in industrial conditions give grounds for its use as an effective tool for the treatment of subclinical and clinical mastitis.